UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the Month of June, 2017

Commission File Number 001-35948

Kamada Ltd.
(Translation of registrant's name into English)
 
2 Holzman Street
Science Park, P.O. Box 4081,
Rehovot 7670402
Israel
  (Address of principal executive offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F T   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
This Form 6-K is being incorporated by reference into the Registrant's Form S-8 Registration Statements, File Nos. 333-192720, 333-207933 and 333-215983, and the Registrant's Form F-3 Registration Statement, as amended, File No. 333-214816.
 


The following exhibit is attached:

99.1
News Release: Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease
 
 

 
SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: July 20, 2017
 
KAMADA LTD.
 
  
 
By:  /s/ Gil Efron
  
 
Gil Efron
 Deputy Chief Executive Officer and Chief Financial Officer
  




EXHIBIT INDEX

EXHIBIT NO.
DESCRIPTION
 
99.1
 
News Release: Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease